ZNTL Zentalis Pharmaceuticals, Inc.
2.550USD-4.49%Mkt Cap: 250.21M $P/E: —1d ago
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenose…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Sector Update: Healthcare Stocks Decline Late Afternoon Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a | ||
 ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program. | ||